Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics Guidances Will Take A Broad Approach

This article was originally published in The Pink Sheet Daily

Executive Summary

The plan is a shift from FDA’s previous intention to issue “product-specific” guidances.

You may also be interested in...



Follow-On Biologics Bill From Rep. Waxman To Be Introduced This Year

Legislation would allow FDA to take a “case-by-case” approach to approving generic versions of BLAs.

Follow-On Biologics Bill From Rep. Waxman To Be Introduced This Year

Legislation would allow FDA to take a “case-by-case” approach to approving generic versions of BLAs.

EMEA Product-By-Product Biosimilar Guidelines To Continue With Alfa Interferon

Additional product-level annexes to European biosimilar guidelines will be created as needed, German regulatory official Weise says.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel